Influence of losartan on structural and functional remodelling of cardiovascular system in comorbidity of chronic obstructive lung disease and arterial hypertension
https://doi.org/10.15829/1728-8800-2016-5-11-16
Abstract
Aim. To assess the influence of losartan treatment for comorbid chronic obstructive lung disease (COPD) and arterial hypertension (AH) on arterial pressure variability (BP), diastolic function and remodelling of the left ventricle myocardium (LV).
Material and methods. Totally, 50 patients with AH and COPD included, mean age 59,8±7,9 y. Depending on the level of mean-daily BP variability (BPV) patients were selected to subgroups with normal (n=15) and increased (n=35) BPV.
Results. Patients with normal BPV had concentric hypertrophy type of LV and moderate diastolic dysfunction of LV mostly with relaxation disorder, but in COPD+AH with higher BPV patients there were more prominent structural and geometric LV disorders with tendency to eccentric LV hypertrophy, as more significant diastolic function disorders with the part of patients having pseudonormal diastolic dysfunction type.
Conclusion. With inclusion of losartan to the protocol of patients’ treatment, there is decrease of structural impairment of the LV that is the lowering of end diastolic LV size, LV myocardial mass, increase of ejection fraction, increase of the number of patients having normal LV geometry, decrease of signs of diastolic dysfunction. In losartan prescription, there is better adherence of patients to treatment.
About the Authors
V. A. NikitinRussian Federation
L. V. Vasilieva
Russian Federation
E. V. Gosteva
Russian Federation
L. V. Pishnograeva
Russian Federation
References
1. Caroli NA, Rebrov AP. Endothelial dysfunction and its clinical significance in patients with chronic obstructive pulmonary disease. Clinical medicine 2005; (9):10-6.
2. Russian (Кароли Н. А., Ребров А. П. Эндотелиальная дисфункция и ее клиническое значение у больных хронической обструктивной болезнью легких. Клиническая медицина 2005; (9): 10-6).
3. Thorn MD. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD EurRespir J 2008; 32 (4): 962-9.
4. Avdeev SN. Intensive therapy in pulmonology. Monograph/Ed. by S. N. Avdeev. Series of monographs Russian respiratory society/ Ed. by A. G. Chuchalin so 1, Chapter 6. Exacerbation of chronic obstructive pulmonary disease. Ed-in the Atmosphere of 2014. S. 153-82. Russia. (Авдеев С. Н. Интенсивная терапия в пульмонологии. Монография. Под ред. С. Н. Авдеева. Серия монографий Российского респираторного общества. Под ред. А. Г. Чучалина. Т. 1, глава 6. Обострение хронической обструктивной болезни легких. Изд-во Атмосфера 2014. С.153-82).
5. Zadionchenko V S, Adasheva TV, Pogonchenkov IV. Arterial hypertension in patients with chronic obstructive lung diseases. Clinico-functional features, the choice of therapy. Cardiovascular Therapy and Prevention 2004; 5 (3): 33-42. Russian (Задионченко В. С., Адашева Т. В., Погонченкова И. В. и др. Артериальная гипертензия у больных хроническими обструктивными болезнями легких. Клинико-функциональные особенности, выбор терапии. Кардиоваскулярная терапия и профилактика 2004; 5 (3): 33-42).
6. Belenkov YN. Remodeling of the left ventricle: an integrated approach. Cent failure 2002; 4(14): 161-3. Russian (Беленков Ю. Н. Ремоделирование левого желудочка: комплексный подход. Сердечная недостаточность 2002; 4 (14): 161-3).
7. Agabiti-Rosei E, Muiesan ML. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10: 288-98.
8. Recommendations for treatment of hypertension ESH/ESC 2013 Russ J Cardiol 2014; 1 (105): 7-94. Russia (Рекомендации по лечению артериальной гипертонии ESH/ESC 2013 Российский кардиологический журнал 2014; 1 (105): 7-94).
9. Shustov SB, Barsukov AB, Al-Yazidi MA, et al. Features of remodeling in patients with arterial hypertension depending on the degree of daily variability in blood pressure. Arterial hypertension 2002; 8 (2): 54-7. Russian (Шустов С. Б., Барсуков А. Б., Аль-Язиди М.А. и др. Особенности ремоделирования у пациентов с артериальной гипертензией в зависимости от степени среднесуточной вариабельности артериального давления. Артериальная гипертензия 2002; 8 (2): 54-7).
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2014 report is available on www.goldcopd.com
11. Recommendations for quantification of the structure and function of the heart chambers. Russ J Cardiol, Suppl. 1 2012; 3 (95): 28 p. Russian (Рекомендации по количественной оценке структуры и функции камер сердца. Российский кардиологический журнал, Приложение 1, 2012; 3 (95): 28 с).
12. Diagnosis and treatment of hypertension. Russian recommendations (fourth revision). Systemic hypertension. 2010; 3: 3-25. Russian (Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр). Системные гипертензии 2010; 3: 3-25).
13. Devereux RB, Okin PM, Roman MJ. Left ventricular hypertrophy as a surrogate endpoint in hypertension. Clin Exp Hypertens 1999; 21: 583-93.
14. Brilla CG, Pick R, Jalil JE, et al. Remodelling of the rat right and left ventricle in experimental hypertension. CircRes 1990; 67: 1355-64.
Review
For citations:
Nikitin V.A., Vasilieva L.V., Gosteva E.V., Pishnograeva L.V. Influence of losartan on structural and functional remodelling of cardiovascular system in comorbidity of chronic obstructive lung disease and arterial hypertension. Cardiovascular Therapy and Prevention. 2016;15(5):11-16. (In Russ.) https://doi.org/10.15829/1728-8800-2016-5-11-16